MIMEDX GROUP INC (MDXG) Stock Fundamental Analysis
USA - NASDAQ:MDXG - US6024961012 - Common Stock
6.72 USD
-0.02 (-0.3%)
6.72 USD
0 (0%)
MDXG gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. MDXG has an excellent financial health rating, but there are some minor concerns on its profitability. MDXG has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
MDXG had positive earnings in the past year.
In the past year MDXG had a positive cash flow from operations.
In multiple years MDXG reported negative net income over the last 5 years.
In multiple years MDXG reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 11.05%, MDXG belongs to the top of the industry, outperforming 94.01% of the companies in the same industry.
MDXG has a Return On Equity of 14.85%. This is amongst the best in the industry. MDXG outperforms 94.38% of its industry peers.
The Return On Invested Capital of MDXG (13.37%) is better than 95.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 14.85% | ||
| ROIC | 13.37% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of MDXG (8.84%) is better than 91.95% of its industry peers.
MDXG's Operating Margin of 12.07% is amongst the best of the industry. MDXG outperforms 92.70% of its industry peers.
In the last couple of years the Operating Margin of MDXG has remained more or less at the same level.
Looking at the Gross Margin, with a value of 81.45%, MDXG belongs to the top of the industry, outperforming 85.39% of the companies in the same industry.
MDXG's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.07% | ||
| PM (TTM) | 8.84% | ||
| GM | 81.45% |
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MDXG is still creating some value.
MDXG has more shares outstanding than it did 1 year ago.
MDXG has more shares outstanding than it did 5 years ago.
MDXG has a better debt/assets ratio than last year.
2.2 Solvency
MDXG has an Altman-Z score of 10.12. This indicates that MDXG is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 10.12, MDXG belongs to the best of the industry, outperforming 82.40% of the companies in the same industry.
The Debt to FCF ratio of MDXG is 0.32, which is an excellent value as it means it would take MDXG, only 0.32 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of MDXG (0.32) is better than 95.88% of its industry peers.
A Debt/Equity ratio of 0.08 indicates that MDXG is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.08, MDXG is doing worse than 62.55% of the companies in the same industry.
Even though the debt/equity ratio score it not favorable for MDXG, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | 0.32 | ||
| Altman-Z | 10.12 |
ROIC/WACC1.43
WACC9.34%
2.3 Liquidity
MDXG has a Current Ratio of 4.39. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.39, MDXG is in line with its industry, outperforming 48.88% of the companies in the same industry.
A Quick Ratio of 3.90 indicates that MDXG has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.90, MDXG is in line with its industry, outperforming 47.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.39 | ||
| Quick Ratio | 3.9 |
3. Growth
3.1 Past
The earnings per share for MDXG have decreased strongly by -54.39% in the last year.
The Revenue has been growing slightly by 6.85% in the past year.
Measured over the past years, MDXG shows a small growth in Revenue. The Revenue has been growing by 3.11% on average per year.
EPS 1Y (TTM)-54.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)6.85%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%13.07%
3.2 Future
The Earnings Per Share is expected to grow by 15.23% on average over the next years. This is quite good.
Based on estimates for the next years, MDXG will show a quite strong growth in Revenue. The Revenue will grow by 12.54% on average per year.
EPS Next Y14.31%
EPS Next 2Y9.89%
EPS Next 3Y15.23%
EPS Next 5YN/A
Revenue Next Year11.61%
Revenue Next 2Y9.88%
Revenue Next 3Y10.48%
Revenue Next 5Y12.54%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 25.85, MDXG can be considered very expensive at the moment.
Based on the Price/Earnings ratio, MDXG is valued cheaply inside the industry as 94.38% of the companies are valued more expensively.
MDXG is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.77, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 19.19, which indicates a rather expensive current valuation of MDXG.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 93.45% of the companies listed in the same industry.
MDXG's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.23.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.85 | ||
| Fwd PE | 19.19 |
4.2 Price Multiples
MDXG's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MDXG is cheaper than 94.38% of the companies in the same industry.
MDXG's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MDXG is cheaper than 95.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.32 | ||
| EV/EBITDA | 16.47 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MDXG does not grow enough to justify the current Price/Earnings ratio.
MDXG has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as MDXG's earnings are expected to grow with 15.23% in the coming years.
PEG (NY)1.81
PEG (5Y)N/A
EPS Next 2Y9.89%
EPS Next 3Y15.23%
5. Dividend
5.1 Amount
No dividends for MDXG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
6.72
-0.02 (-0.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners71.57%
Inst Owner Change-0.8%
Ins Owners1.83%
Ins Owner Change0.64%
Market Cap994.29M
Revenue(TTM)363.77M
Net Income(TTM)32.17M
Analysts81.82
Price Target12.44 (85.12%)
Short Float %3.27%
Short Ratio7.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.25%
Min EPS beat(2)6.95%
Max EPS beat(2)81.55%
EPS beat(4)3
Avg EPS beat(4)17%
Min EPS beat(4)-31.92%
Max EPS beat(4)81.55%
EPS beat(8)7
Avg EPS beat(8)68.99%
EPS beat(12)10
Avg EPS beat(12)59.73%
EPS beat(16)12
Avg EPS beat(16)49.94%
Revenue beat(2)2
Avg Revenue beat(2)3.5%
Min Revenue beat(2)0.32%
Max Revenue beat(2)6.68%
Revenue beat(4)3
Avg Revenue beat(4)2.13%
Min Revenue beat(4)-0.35%
Max Revenue beat(4)6.68%
Revenue beat(8)6
Avg Revenue beat(8)1.52%
Revenue beat(12)8
Avg Revenue beat(12)2.12%
Revenue beat(16)12
Avg Revenue beat(16)2.46%
PT rev (1m)0%
PT rev (3m)1.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)20.69%
EPS NY rev (1m)0%
EPS NY rev (3m)28.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.32%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.85%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.85 | ||
| Fwd PE | 19.19 | ||
| P/S | 2.73 | ||
| P/FCF | 17.32 | ||
| P/OCF | 17.11 | ||
| P/B | 4.59 | ||
| P/tB | 5.37 | ||
| EV/EBITDA | 16.47 |
EPS(TTM)0.26
EY3.87%
EPS(NY)0.35
Fwd EY5.21%
FCF(TTM)0.39
FCFY5.77%
OCF(TTM)0.39
OCFY5.85%
SpS2.46
BVpS1.46
TBVpS1.25
PEG (NY)1.81
PEG (5Y)N/A
Graham Number2.93
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 14.85% | ||
| ROCE | 18.24% | ||
| ROIC | 13.37% | ||
| ROICexc | 26.4% | ||
| ROICexgc | 35.58% | ||
| OM | 12.07% | ||
| PM (TTM) | 8.84% | ||
| GM | 81.45% | ||
| FCFM | 15.78% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-47.46%
ROICexc growth 3YN/A
ROICexc growth 5Y-21.46%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
F-Score5
Asset Turnover1.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | 0.32 | ||
| Debt/EBITDA | 0.32 | ||
| Cap/Depr | 6.78% | ||
| Cap/Sales | 0.2% | ||
| Interest Coverage | 28.3 | ||
| Cash Conversion | 106.77% | ||
| Profit Quality | 178.44% | ||
| Current Ratio | 4.39 | ||
| Quick Ratio | 3.9 | ||
| Altman-Z | 10.12 |
F-Score5
WACC9.34%
ROIC/WACC1.43
Cap/Depr(3y)52.31%
Cap/Depr(5y)58.09%
Cap/Sales(3y)0.72%
Cap/Sales(5y)1.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-54.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next Y14.31%
EPS Next 2Y9.89%
EPS Next 3Y15.23%
EPS Next 5YN/A
Revenue 1Y (TTM)6.85%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%13.07%
Revenue Next Year11.61%
Revenue Next 2Y9.88%
Revenue Next 3Y10.48%
Revenue Next 5Y12.54%
EBIT growth 1Y-29.45%
EBIT growth 3YN/A
EBIT growth 5Y2.02%
EBIT Next Year35.54%
EBIT Next 3Y15.54%
EBIT Next 5YN/A
FCF growth 1Y1521.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6349.89%
OCF growth 3YN/A
OCF growth 5YN/A